Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...
The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down pharmaceutical giant: Pfizer ( PFE +0.02%). Let's see what's happening between ...
Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback